Targeting Programmed Cell Death 1 in Ovarian Cancer

J Clin Oncol. 2015 Dec 1;33(34):3987-9. doi: 10.1200/JCO.2015.63.7785. Epub 2015 Oct 26.

Authors

Krisztian Homicsko¹, George Coukos²

Affiliations

¹ Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
² Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Ludwig Institute Branch at the University of Lausanne, Lausanne, Switzerland george.coukos@chuv.ch.

PMID: 26503205
DOI: 10.1200/JCO.2015.63.7785

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Neoplasm Recurrence, Local / drug therapy*
Ovarian Neoplasms / drug therapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Salvage Therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Programmed Cell Death 1 Receptor